Background: Drug eluting stents with biodegradable polymers have been developed to address the risk of very late adverse events. Long-term comparison data between the biodegradable polymer-coated biolimus-eluting stent (BES; Nobori®) and the second-generation durable polymer-coated everolimus-eluting stent (EES; XIENCE V® or XIENCE PRIME® or PROMUS™) in diabetic patients are scarce.
Methods: The COMPARE II trial was an investigator-initiated, multicenter, open-label, randomized, all-comers trial which assigned patients undergoing percutaneous coronary intervention (PCI) in a 2:1 fashion to either BES or EES.We analyzed the safety and efficacy outcomes in diabetic patients at 5 year follow-up. The primary pre-specified composite endpoint major adverse cardiac event (MACE) was defined as cardiac death, non-fatal target-vessel myocardial infarction (TV-MI), or clinically indicated target vessel revascularization (CD-TVR).
Results: Out of 2707 study patients, 588 were diabetics of whom 391 were treated with BES and 197 with EES. At 5 years follow-up, MACE occurred in 87 patients in the BES group and in 34 patients in the EES group. Other safety and efficacy endpoints did not differ between stent groups.
Conclusions: At 5 years follow-up, no differences in terms of MACE as well as all analyzed safety and efficacy measures, including stent thrombosis, between the biodegradable polymer-coated BES and the durable polymercoated EES in diabetic patients were observed

Biodegradable polymer, Diabetes mellitus, Drug eluting stents,
International Journal of Cardiology
Department of Hematology

Paradies, V, Vlachojannis, G.J, Royaards, K.-J, Wassing, J, van der Ent, M, & Smits, P.C. (2019). Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes mellitus 5 years follow-up from the COMPARE II trial. International Journal of Cardiology, 290, 40–44. doi:10.1016/j.ijcard.2019.04.054